WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317200
CAS#: 200815-49-2 (tartrate)
Description: Arformoterol tartrate is a long acting beta-adrenoceptor agonist drug indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization. It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.
MedKoo Cat#: 317200
Name: Arformoterol tartrate
CAS#: 200815-49-2 (tartrate)
Chemical Formula: C23H30N2O10
Molecular Weight: 494.5
Elemental Analysis: C, 55.87; H, 6.12; N, 5.67; O, 32.35
Related CAS #: 200815-49-2 (tartrate) 67346-49-0(free base) 1254575-18-2 (maleate)
Synonym: (R,R)-Formoterol; Formoterol; arformoterol; BD 40A; eformoterol; Foradil; formoterol fumarate; Oxis
IUPAC/Chemical Name: N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-formamide (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt)
InChi Key: FCSXYHUNDAXDRH-OKMNHOJOSA-N
InChi Code: InChI=1S/C19H24N2O4.C4H6O6/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-1(3(7)8)2(6)4(9)10/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2,5-6H,(H,7,8)(H,9,10)/t13-,19+;1-,2-/m11/s1
SMILES Code: O=CNC1=CC([C@@H](O)CN[C@H](C)CC2=CC=C(OC)C=C2)=CC=C1O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 494.5 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Loh CH, Donohue JF, Ohar JA. Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015 Mar;14(3):463-72. doi: 10.1517/14740338.2015.998196. Epub 2015 Jan 7. Review. PubMed PMID: 25563342.
2: Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin DP. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec;146(6):1531-42. doi: 10.1378/chest.14-0117. PubMed PMID: 25451347; PubMed Central PMCID: PMC4251615.
3: Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:631-9. doi: 10.2147/COPD.S52557. Epub 2013 Dec 5. PubMed PMID: 24353413; PubMed Central PMCID: PMC3858026.
4: Miles MC, Donohue JF, Ohar JA. Nebulized arformoterol: what is its place in the management of COPD? Ther Adv Respir Dis. 2013 Apr;7(2):81-6. doi: 10.1177/1753465812465784. Epub 2012 Nov 12. Review. PubMed PMID: 23147985.
5: Das SK, Biswas I, Bandyopadhyay AK, Bairagya TD, Bhattacharya S. A comparative study of efficacy and safety of arformoterol and salbutamol nebulization as rescue therapy in acute non-severe asthma. Indian J Pharmacol. 2011 Jul;43(4):463-5. doi: 10.4103/0253-7613.83123. PubMed PMID: 21845007; PubMed Central PMCID: PMC3153715.
6: Hinkle J, Hinson J, Kerwin E, Goodwin E, Sciarappa K, Curry L, Hanrahan JP. A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma. Pediatr Pulmonol. 2011 Aug;46(8):761-9. doi: 10.1002/ppul.21446. Epub 2011 May 16. PubMed PMID: 21584948.
7: Cazzola M, Hanania NA, Matera MG. Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med. 2010 Apr;4(2):155-62. doi: 10.1586/ers.10.16. Review. PubMed PMID: 20406080.
8: Hanania NA, Donohue JF, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, Hanrahan JP. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb;7(1):17-31. doi: 10.3109/15412550903499498. PubMed PMID: 20214460.
9: Bauer A, McGlynn P, Bovet LL, Mims PL, Curry LA, Hanrahan JP. The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator. Respir Care. 2009 Nov;54(11):1488-92. PubMed PMID: 19863833.
10: Panettieri RA Jr, MacIntyre N, Sims M, Kerwin E, Fogarty C, Noonan M, Claus R, Andrews WT. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study. Clin Ther. 2009 Aug;31(8):1716-23. doi: 10.1016/j.clinthera.2009.08.012. PubMed PMID: 19808130.